The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. - Wikidata - wikimedia - TriplyDB

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

http://www.wikidata.org/entity/Q36467579

about

Clinical trials in severe sepsis with drotrecogin alfa (activated)Recently published papers: A clinical conundrum, new from old and advances in ventilation?Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults One year outcomes in patients with acute lung injury randomised to initial trophic or full enteral feeding: prospective follow-up of EDEN randomised trial Using data-driven rules to predict mortality in severe community acquired pneumonia.Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Practical aspects of treatment with drotrecogin alfa (activated)Mortality and quality of life in the five years after severe sepsis Long-term mortality after critical care: what is the starting point?The effect of window rooms on critically ill patients with subarachnoid hemorrhage admitted to intensive care.Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study Acute and long-term survival in chronically critically ill surgical patients: a retrospective observational study A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care.Drotrecogin alfa (activated): real-life use and outcomes for the UK Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.Model for predicting short-term mortality of severe sepsis Effect of sepsis therapies on health-related quality of life.Association of Delayed Antimicrobial Therapy with One-Year Mortality in Pediatric Sepsis.Reporting data on long-term follow-up of critical care trials.Understanding and improving clinical trial outcome measures in acute respiratory failure.Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.

P2860

Q21195024-09C387A0-2C6F-496F-9A41-88FCB1367185 Q24802928-7E30B2FF-10DC-450C-81C1-1976543192C2 Q28079305-A5BD02D6-2523-4F6D-9731-0DA68A527423 Q28661096-80B0E322-3E7F-420F-AAA1-F534A1E1E762 Q28743919-651739C3-3DE9-40E6-B660-7F02BED2AE8F Q30421818-EA746B44-F3B5-4ED6-9F03-149A4AA62E62 Q30793094-C3FA09E3-F27D-4F1C-9A2D-8B847D423F9F Q33288889-8BD11FBA-290F-4587-B990-8FFA7478DE81 Q33378616-4F64EBD1-8656-4D86-9D49-3E7682D4296D Q33754061-F77CC864-EB59-4EA5-A014-21D88201FEB2 Q33762203-AB64F3AE-50FF-4D53-8CA1-AEB4A84C3B7F Q35559367-AFD7E87B-33E9-4D73-B049-7EEF973BD0DD Q35873550-FFFD54A4-AA95-4719-B0B1-8957231A9DA3 Q36392442-71A4BB21-6950-4049-A2FC-BE83B9030D34 Q36465434-DDF40353-2F12-401C-95DD-9AE8B776E73B Q36749140-C0320723-C7CF-4AF2-B1D0-BDF6290E232B Q37106071-3E68B421-6B2D-4B95-BBF5-08F55DB8E88E Q37241529-CB847A79-FCCA-415C-ADB7-DF355EA9532D Q37279786-36536869-1F89-452F-8DB1-E66B8DED9C8D Q38275323-8919483A-D3D5-4AFD-B248-D4EE2086FEAB Q38766827-CE0EA5B8-25E0-405E-BDBA-3631A84AB0A7 Q42346534-F1737658-49AC-41D7-A9AF-C2C30F394731 Q42735846-B3B4C9A0-6A97-4380-B3D4-40A7CE7FCA3C Q43182531-30785151-D5ED-4D0A-B3D0-21634B524855

P2860

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

http://www.wikidata.org/entity/Q36467579

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@ast

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@en

type

label

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@ast

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@en

prefLabel

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@ast

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@en

P1433

Q36467579-A18F1F40-437A-493F-BB68-6BAA9847E8B6

P1476

Q36467579-D65961A3-6424-4E23-8C3F-F2B1F7AD0703

P2093

Q36467579-01E49F3D-BA97-4667-AB98-09C2930F76BA

Q36467579-1F2798DC-C971-43E1-B9A3-FDB41E85A9E7

Q36467579-3FC87B41-1D8B-4BA0-8D64-E17682AC51B9

Q36467579-5F102959-7CD4-4B73-AB5A-4891F38B352C

Q36467579-80CA8F8B-4C4D-4029-A974-09656407F22F

Q36467579-AF94762C-D530-4148-9D6E-72BBE5D8CBFF

Q36467579-D76D37DF-713E-4F8D-9DFE-F338629FAE98

P2860

Q36467579-0B1160B1-E0C7-4612-B883-00D1C087DFE8

Q36467579-0BB4544C-9142-4C9E-A41C-FFEFA60FDEC8

Q36467579-1B698040-C1AB-405A-B35F-05CE82EC803D

Q36467579-1F44F039-2645-4D6E-A264-0E702F176CA8

Q36467579-35BEB63E-08CC-4D15-8660-D36CA6DA81F8

Q36467579-44FBA356-2BE7-437F-B79F-7849404B7A3B

Q36467579-49613A34-A20E-478F-A004-98177F95517E

Q36467579-5D11EF3E-3B37-4639-8018-72746996D02A

Q36467579-5E02353B-6A9B-4372-A8D0-0F3794723838

Q36467579-626A1E8B-AE20-4B31-9D6E-B2EA9A22E132

P304

Q36467579-C19C1FE7-47CF-489B-943C-C4F551EE3A50

P31

Q36467579-912F6BA4-AD98-4A3E-BDC0-204046B5BFFA

P407

Q36467579-6470207A-9C15-4AA9-8F10-BD4EDC9B1391

P433

Q36467579-795AFB2F-B9FD-45B8-AD88-FFB77B6D6E25

P478

Q36467579-2C7B9EEC-4F86-47AE-9587-669F975F176B

P50

Q36467579-6DAF0EFD-66E6-4029-81E0-3D0902E1FA2F

Q36467579-9135C8CB-7BCD-4E1F-88A8-05EAE6108773

P577

Q36467579-089A800D-9DD4-4450-A9E3-E16CA99C2775

P698

Q36467579-13214815-5DC0-4D26-8929-0BE14B575559

P921

Q36467579-5CA1F53B-1606-477A-96C4-62F071B98732

P932

Q36467579-BB2123E7-845E-4563-9A7D-FE658DA5165B

P1433

Critical Care Medicine

P1476

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

@en

P2093

Daniel E Ball

http://www.w3.org/2001/XMLSchema#string

Gordon R Bernard

http://www.w3.org/2001/XMLSchema#string

Jeff Helterbrand

http://www.w3.org/2001/XMLSchema#string

Lisa A Weissfeld

http://www.w3.org/2001/XMLSchema#string

PROWESS Investigators

http://www.w3.org/2001/XMLSchema#string

Pierre-Francois Laterre

http://www.w3.org/2001/XMLSchema#string

Rekha Garg

http://www.w3.org/2001/XMLSchema#string

P2860

Severe sepsis: variation in resource and therapeutic modality use among academic centers

Variation in sepsis care: a wake-up call

Early goal-directed therapy in the treatment of severe sepsis and septic shock

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

APACHE II: a severity of disease classification system

Efficacy and safety of recombinant human activated protein C for severe sepsis

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.

Risks and benefits of activated protein C treatment for severe sepsis.

P304

2199-2206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Wesley Ely

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15640631

http://www.w3.org/2001/XMLSchema#string

P921

P932

4714718

http://www.w3.org/2001/XMLSchema#string